0.74
-0.033(-4.29%)
Currency In USD
| Previous Close | 0.77 |
| Open | 0.76 |
| Day High | 0.78 |
| Day Low | 0.74 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.63 |
| Volume | 330,492 |
| Average Volume | 941,475 |
| Market Cap | 15.52M |
| PE | 2.95 |
| EPS | 0.25 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.27 |
| Change | -0.03 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $9.95 as of November 07, 2025 at a share price of $0.737. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $22.33 as of November 07, 2025 at a share price of $0.737.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
GlobeNewswire Inc.
Oct 28, 2025 1:15 PM GMT
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will re
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
GlobeNewswire Inc.
Oct 27, 2025 1:15 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
GlobeNewswire Inc.
Oct 06, 2025 1:15 PM GMT
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will pa